Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.75 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.56 |
| ▸ | IGF2R | P11717 | 4/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.43 |
| ▸ | UMPS | P11172 | 3/20 | 0.42 |
| ▸ | ATIC | P31939 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15765675 | 1.00 | FBP1 (0.75) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL14503325 | 1.00 | FBP1 (0.75) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL14985153 | 1.00 | FBP1 (0.75) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL18294135 | 1.00 | FBP1 (0.75) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL10064521 | 1.00 | FBP1 (0.75) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL19454793 | 1.00 | FBP1 (0.75) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL13857406 | 0.98 | FBP1 (0.72) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL29323929 | 0.98 | FBP1 (0.72) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL18710783 | 0.98 | FBP1 (0.72) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL29324521 | 0.98 | FBP1 (0.72) | FBP1AMDHD2IGF2RP2RY2P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321131-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT AND PREVENTION OF AN ANTINEOPLASTIC-INDUCED TOXICITY | NUVAMID SA (CH) | 2023-10-12 | — | — | US | disclosed |
| US-11730752-B2 | Use of NMN for the prevention and/or treatment of joint pain induced by physical activity, and corresponding compositions | NUVAMID SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-20230210881-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | NUVAMID SA (CH) | 2023-07-06 | — | — | US | disclosed |
| US-20230210746-A1 | ANTI-AGING COSMETIC COMPOSITIONS COMPRISING NMN | NUVAMID SA (CH) | 2023-07-06 | — | — | US | disclosed |
| US-20230172959-A1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF A BACK PAIN AND CORRESPONDING COMPOSITIONS | NUVAMID SA (CH) | 2023-06-08 | — | — | US | disclosed |
| US-20230150984-A1 | NICOTINAMIDE MONONUCLEOTIDE AND NICOTINAMIDE RIBOSIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS AND RESPIRATORY COMPLICATIONS, IN PARTICULAR CAUSED BY INFLUENZAVIRUS OR CORONAVIRUS | NUVAMID SA (CH) | 2023-05-18 | — | — | US | disclosed |
| US-20230136569-A1 | USE OF NMN TO REDUCE IMMUNODEPRESSION AND IMMUNOSENESCENCE | NUVAMID SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230096443-A1 | NOVEL NICOTINAMIDE DI-NUCLEOTIDE DERIVATIVES AND USE THEREOF | NUVAMID SA (CH) | 2023-03-30 | — | — | US | disclosed |
| US-20230060438-A1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF JOINT PAIN INDUCED BY PHYSICAL ACTIVITY, AND CORRESPONDING COMPOSITIONS | NUVAMID SA (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20210353656-A1 | COMBINATION OF NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND HISTAMINE H2 RECEPTOR ANTAGONISTS FOR VIRAL INFECTIONS | NUVAMID SA (CH) | 2021-11-18 | — | — | US | disclosed |
| US-20210332033-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS | NUVAMID SA (CH) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172959-A1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF A BACK PAIN AND CORRESPONDING COMPOSITIONS | NNT, NAMPT, UTRN | FBP1 334/4885AMDHD2 517/4885IGF2R 3637/4885 |
| US-20230150984-A1 | NICOTINAMIDE MONONUCLEOTIDE AND NICOTINAMIDE RIBOSIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS AND RESPIRATORY COMPLICATIONS, IN PARTICULAR CAUSED BY INFLUENZAVIRUS OR CORONAVIRUS | NAMPT, NNT, NADK | FBP1 154/4885AMDHD2 101/4885IGF2R 1773/4885 |
| US-20230060438-A1 | USE OF NMN FOR THE PREVENTION AND/OR TREATMENT OF JOINT PAIN INDUCED BY PHYSICAL ACTIVITY, AND CORRESPONDING COMPOSITIONS | NNT, NAMPT, NMUR1 | FBP1 1061/4885AMDHD2 261/4885IGF2R 3352/4885 |
| US-20210353656-A1 | COMBINATION OF NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND HISTAMINE H2 RECEPTOR ANTAGONISTS FOR VIRAL INFECTIONS | HRH2, HRH4, HRH3 | FBP1 470/4885AMDHD2 186/4885IGF2R 583/4885 |
| US-20230210881-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | NNT, NAMPT, ME1 | FBP1 118/4885AMDHD2 155/4885IGF2R 1207/4885 |
| US-20230321131-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT AND PREVENTION OF AN ANTINEOPLASTIC-INDUCED TOXICITY | NAMPT, NNT, NQO1 | FBP1 375/4885AMDHD2 122/4885IGF2R 2893/4885 |
| US-11730752-B2 | Use of NMN for the prevention and/or treatment of joint pain induced by physical activity, and corresponding compositions | NNT, NAMPT, NMUR1 | FBP1 1061/4885AMDHD2 261/4885IGF2R 3352/4885 |
| US-20230210746-A1 | ANTI-AGING COSMETIC COMPOSITIONS COMPRISING NMN | NCL, POLN, CUTA | FBP1 3695/4885AMDHD2 102/4885IGF2R 4504/4885 |
| US-20230136569-A1 | USE OF NMN TO REDUCE IMMUNODEPRESSION AND IMMUNOSENESCENCE | NAMPT, NNT, NNMT | FBP1 1251/4885AMDHD2 67/4885IGF2R 1681/4885 |
| US-20230096443-A1 | NOVEL NICOTINAMIDE DI-NUCLEOTIDE DERIVATIVES AND USE THEREOF | NNT, NAMPT, NQO1 | FBP1 1241/4885AMDHD2 411/4885IGF2R 4537/4885 |
| US-20210332033-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS | NAMPT, NNT, NNMT | FBP1 200/4885AMDHD2 87/4885IGF2R 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.